Vardi M,,Jacobson E,Nini A,et al.Intermediate acting versus long acting insulin for type 1 diabetes mellitus.Cochrane Database of Systematic Reviews. 2008Vardi M, Eyal J, Asaph N, Haim B: Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database of ...
The progressive nature of type 2 diabetes necessitates exogenous insulin use for most patients; basal insulin plus oral anti-diabetes drugs (OADs) is a well-validated way to facilitate insulin initiation. The primary aim of this study was to explore insulin initiation strategies and outcomes for ...
Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes. OBJECTIVE — Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations... Home,Philip,Bartley,... - 《Diabetes...
Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1... Koehler G, Treiber G, Wutte A.Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under ...
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGI... Basal insulin therapy does not stop loss of β-cell function, which is the hallmark of type 2 diabetes mellitus, and thus diabetes cont...
Insulin icodec is a once-weekly basal insulin that may improve treatment acceptance and adherence by reducing the number of basal insulin injections from at least 365 per year to 52 per year.3 Clinical trials have demonstrated that icodec has a long half-life of approximately 1 week, with phas...
(fasting C-peptide >0.5 nmol/L) and who were using long-acting insulin. Exclusion criteria weretype 1 diabetes, a history ofketoacidosis, and use of noninsulin injectable glucose-lowering medication. The complete list of eligibility criteria can be found inAppendix 1(available online atwww.gie...
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target ba... Aims This 24-month, multi-national, open-label, parallel group trial investigated the long-term efficacy and safety of insulin detemir ...
Insulin Degludec Improves Glycemic Control with Lower Nocturnal Hypoglycemia Risk than Insulin Glargine: A 2-year Randomized Trial in Type 1 Diabete This 2-yr, open-label study compared efficacy and safety of insulin degludec (IDeg), a new, ultra-long-acting basal insulin, and insulin glargine ...
Substituting the evening intermediate acting insulin with a long acting insulin analogue (LAIA) at dinner in a twice daily (BID) injection regimen may be as effective as a TID regimen. The objective of this pilot study was to compare HbA1c in children with DM1 using a BID regimen with a ...